English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse
  1. View item / 
  2. Item Summary

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

Coronavirus-Replikation: Mechanismus und Inhibition durch Remdesivir

MPS-Authors
/persons/resource/persons127020

Cramer,  P.
Department of Molecular Biology, MPI for Biophysical Chemistry, Max Planck Society;

/persons/resource/persons186186

Kokic,  G.
Department of Molecular Biology, MPI for Biophysical Chemistry, Max Planck Society;

/persons/resource/persons195449

Dienemann,  C.
Department of Molecular Biology, MPI for Biophysical Chemistry, Max Planck Society;

/persons/resource/persons211404

Hillen,  H. S.
Research Group Structure and Function of Molecular Machines, MPI for Biophysical Chemistry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

3343537.pdf
(Publisher version), 968KB

Supplementary Material (public)
There is no public supplementary material available
Citation

Cramer, P., Kokic, G., Dienemann, C., Höbartner, C., & Hillen, H. S. (2021). Coronavirus-Replikation: Mechanismus und Inhibition durch Remdesivir. Biospektrum, 27(1), 49-53. doi:10.1007/s12268-021-1516-6.


Cite as: https://hdl.handle.net/21.11116/0000-0009-46A7-C
Abstract
Coronaviruses use an RNA-dependent RNA polymerase to replicate and transcribe their RNA genome. The structure of the SARS-CoV-2 poly- merase was determined by cryo-electron microscopy within a short time in spring 2020. The structure explains how the viral enzyme syn- thesizes RNA and how it replicates the exceptionally large genome in a processive manner. The most recent structure-function studies furtherreveal the mechanism of polymerase inhibition by remdesivir, an approved drug for the treatment of COVID-19.